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The spread of carbapenem resistant Enterobacteriaceae (CRE) has recently become a matter of concern in
public health, mainly due to the wide distribution of carbapenemase genes. Italy is a country considered
endemic for the spread of blaKPC Klebsiella pneumoniae (KP). The aim of this study was to depict the epi-
demiological trend of CRE in one Italian hospital over a long period (3 years surveillance, from May 2011
to April 2014). Based on deﬁned MIC cut-off for speciﬁc carbapenems, 164 strains isolated from 146 dif-
ferent patients were analyzed both phenotypically and genotypically to establish the resistance genes.
Molecular typing was performed using the RAPD technique. 77 strains were demonstrated to harbor
the blaKPC gene (73 KP, 4 Escherichia coli – EC), 51 strains the blaVIM gene (44 KP, 3 EC, 2 Enterobacter clo-
acae and 2 Klebsiella oxytoca), 8 the blaNDM gene (3 KP, 4 EC and one Providencia stuartii), 3 the blaOXA-48
gene (2 KP, 1 EC), whereas 25 out of the 164 isolates (of different genera and species) had a negative mul-
tiplex-PCR ampliﬁcation for all the targets tested. 39 out of the 164 strains analyzed (23.8%) revealed dis-
crepancies between the MICs obtained with automated instrument and gradient MICs of more than two
logs of difference; the broth microdilution provided a better agreement with the results obtained with
the gradient MIC. The use of RAPD allowed to distinguish different clusters, closely related, both for blaKPC
and for blaVIM KP.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The spread of carbapenem resistant Enterobacteriaceae (CRE)
has recently become a matter of concern in public health. The
pattern of resistance is mainly due to the dissemination of
carbapenemase genes. The spread of these multi-drug resistant
organisms appears even more striking considering that the
ﬁrst identiﬁcation of CRE took place almost 20 years ago (USA,
1996) and became public knowledge only in 2001 (Yigit et al.,
2001). To date, three main classes of carbapenemases have been
identiﬁed (Queenan and Bush, 2007). Ambler class A beta-lacta-
mases are enzymes that can be either chromosomally encoded
(blaNMC, blaSME, blaIMI-1, blaSFC-1) or plasmid encoded (blaKPC and,
less common, blaIMI-2, blaGES). Verona integron-encodedmetallo-b-lactamase (blaVIM), blaIMP, and the New Delhi metallo-
b-lactamase (blaNDM) belong to class B metallo-b-lactamases
(MBLs). The characterization of blaNDM was ﬁrstly published in
December 2009 (Yong et al., 2009) and its presence was then
detected in almost the entire world (Cornaglia et al., 2011).
BlaOXA-48 carbapenemases belong to Ambler class D. Finally, of
somehow minor impact and perhaps underestimated, resistance
to carbapenems can also be caused by other mechanisms, such
as hyperexpression of AmpC gene or to decreased permeability of
the outer membrane because of porin loss in combination with
the expression of AmpC enzymes or ESBLs.
The origin of carbapenemase genes was well-deﬁned from the
geographical point of view: KPC b-lactamases were ﬁrst observed
in USA (Yigit et al., 2001) but are nowadays widely diffused world-
wide, particularly in Greece (Tsakris et al., 2008) and Italy (Canton
et al., 2012), VIM gene was ﬁrstly described in Italy (Lauretti et al.,
1999), NDM enzyme was ﬁrstly isolated in Sweden in a patient
with a prolonged stay in India, then in the UK and worldwide
(Kumarasamy et al., 2010; Poirel et al., 2010; Yong et al., 2009),
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southern European countries with a rapid spread in France and
Turkey (Nordmann, 2014; Poirel et al., 2012).
Although a number of bacterial species can harbor carbapenem-
ase genes, they are most commonly described in Klebsiella
pneumoniae (KP) isolates, which can express different resistance
mechanisms such as blaKPC, blaVIM, blaNDM, blaOXA-48 and blaIMP,
due to plasmid distribution.
The spread of CRE has dramatically increased in Italy since
2009. At that time, the percentage of invasive isolates of KP resis-
tant to carbapenems was 1.3%, rising to more than 10% in 2010 and
reaching the rate of 34.3% in 2013 (European Centre for Disease
Prevention and Control, 2010, 2014).
Recently, Monaco et al. pointed out that colistin resistance has
emerged in Italy as an overlapping topic in carbapenem-resistant
KP, making the problem of the carbapenemase-producing Entero-
bacteriaceae (CPE) even more alarming (Monaco et al., 2014).
After a number of different KPC+ KP outbreaks in different hos-
pitals in our region (Emilia-Romagna, Italy), guidelines to control
and prevent the further spread of CPE, were developed by the
Infectious Risk Unit of the Agenzia Sanitaria e Sociale Regionale:
these were based on the most recent scientiﬁc evidence and were
applied from August 2011 (Gagliotti et al., 2011). This centrally-
coordinated intervention lead to a partial containment of the
spread of CPE in the Region (Gagliotti et al., 2014). The epidemio-
logical trend of CRE, within one of the main Emilia-Romagna hos-
pitals which took part in this region-wide intervention, is
described below.
2. Materials and methods
2.1. Setting and study period
The study was performed in the Clinical Microbiology Labora-
tory of the IRCCS Arcispedale Santa Maria Nuova of Reggio Emilia,
Italy. The Laboratory is located in Reggio Emilia, the fourth largest
city in the region Emilia-Romagna. It works as a reference labora-
tory for the detection and conﬁrmation of CPE for the main Hospi-
tal (923 acute care beds) and for a number of smaller district
general hospitals in Reggio Emilia province. The province has an
area of 2292.89 km2 (885.05 mi2), and a total population of
536.618 inhabitants. Geographical details are provided as KML ﬁle
in the Supplemental material. The study was carried out in a 3-year
period, from May 2011 to April 2014, for an overall duration of
36 months.
2.2. Study population and bacterial samples
During the study period all strains of Enterobacteriaceae show-
ing reduced susceptibility to carbapenems, deﬁned as strains with
ertapenem MICsP 1 mcg/ml, and/or imipenem MICsP 2 mcg/ml
and/or meropenem MICsP 2 mcg/ml, were further characterized
using phenotypic tests. The isolates were collected from both
clinical samples and from surveillance screening (rectal swabs).
Basic clinical information of the patients were collected. The
molecular analysis was performed only on the ﬁrst strain isolated
from any patient per year (regardless of the site of isolation), or in
case of isolation of different CPE genera or species in the same
patient. Isolates from the same patient after more than 1 year
were analyzed with molecular techniques as well. For molecular
analysis, ﬁve reference strains known to harbor carbapenemase
genes were included as positive internal quality control for
molecular testing (blaKPC, blaVIM, blaNDM, blaOXA-48 and blaIMP).
These strains were collected from the external quality assessment
services (UK NEQAS) or from previously published studies
(Gaibani et al., 2011).2.3. Phenotypic characterization and susceptibility to carbapenems
In order to initially deﬁne the presence and type of the carba-
penemases involved, we used disk diffusion synergy tests for
detection of MBL and KPC (meropenem disks supplemented with
aminophenylboronic acid, dipicolinic acid and cloxacillin (Rosco,
Denmark) (Doyle et al., 2012). A suspension of 0.5 McFarland of
each strain was used to inoculate a plate of Mueller-Hinton agar
and left to dry; disks of meropenem alone and with combinations
as above were placed into the agar afterwards. In order to improve
the detection of blaOXA-48 strains, we also implemented the test
using a disk of 30 lg disk of temocillin placed in the center of
the plate. The results were read using the manufacturer’s indica-
tion (based on the enlargement of the zone of inhibition towards
the meropenem disks with supplements). Lack of inhibition around
temocillin with a negative synergy test for meropenem – merope-
nem/dipicolinic acid was considered suggestive of an OXA-48 posi-
tive strain. ESBL resistance was conﬁrmed using the procedure
suggested by CLSI (CLSI, 2011). AmpC presence was established
by synergy test using ertapenem versus combinations ertape-
nem + boronic acid and ertapenem + cloxacillin (test provided by
Lioﬁlchem, Italy – unpublished data). For all strains, antimicrobial
susceptibility to carbapenems was evaluated using an automated
instrument, Vitek2 (BioMérieux, France); gradient MIC was
assessed by using MIC test strips (Lioﬁlchem, Italy). The broth mic-
rodilution method, performed according to the recommendations
of CLSI (CLSI, 2011), was used to correctly deﬁne strains showing
a difference of more than two logs with the two above tests.
2.4. Molecular analysis of the carbapenemase genes
Genomic DNA was extracted using the UltraClean™ microbial
DNA isolation kit (MoBio Laboratories, USA) according to the man-
ufacturer’s instructions. A multiplex PCR (based on a slight modiﬁ-
cation of the protocol of Poirel et al.) was used on all isolates to
detect ﬁve carbapenemase genes (blaKPC, blaVIM, blaNDM, blaOXA-48
and blaIMP) (Poirel et al., 2011). The following modiﬁcations were
applied to the original procedure: reactions were performed as sin-
gle multiplex PCR reaction in a ﬁnal volume of 25 ll, the Taq used
was AmpliTaq (Applied Biosystems, USA) and primers used for
ampliﬁcation of blaKPC, which provided a 893 bp band, were: for-
ward (50–30): ATGTCACTGTATCGCCGTCT and reverse (50–30):
TTTTCAGACCCTTACTGCCC. All different experiments were per-
formed using internal controls for the ﬁve different genes.
2.5. Molecular typing
Selected KP strains were analyzed for typing purposes using
both the Enterobacterial Repetitive Intergenic Consensus (ERIC-
PCR) and the random ampliﬁcation of polymorphic DNA (RAPD).
The most discriminating methodology was then applied to type
the different KP isolates. The protocol described by Cartelle et al.
was used for ERIC-PCR, without modiﬁcations (Cartelle et al.,
2004). Five different primers were used for RAPD, four of them
originally used to type staphylococci (Damiani et al., 1996). The
primers used are listed in Table 1.
Ampliﬁcation reactions were performed in a 25 ll volume con-
taining reaction buffer, 5 mM MgCl2, 10 mM dNTPs, 1 lM of each
single primer, 40 ng of DNA and 5 U/ll of Taq Polymerase (Amplit-
aq™, Applied Biosystems, Thermo Scientiﬁc USA). After 5 minutes
of denaturation at 95 C, RAPD ampliﬁcations were cycled 35 times
through the following temperature proﬁle: 95 C – 30 s; 45 C –
1 min and 72 C – 2 min, followed by an elongation phase at
72 C for 10 min. For the primer ED1, the annealing temperature
was set at 38 C. For gel electrophoresis, 5 ll of each ampliﬁcation
product were loaded onto a 2% (w/v) agarose gel.
Table 1
Primers used in this study.
NP2: 50-CGGGGGACTGTTGGGCGCCATCT-30
NP3: 50-GAAGCAGCCCGGTAGTAGGTTGAG-30
NP4: 50-CTAATGCAGGAGTCGCATAAGGGAGA-30
NP5: 50-AGCGCTGTGAGAAAGATGA-30
ED1: 50-CCGTCGGAGCC-30
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band of diverse size, regardless of the intensity of the bands,
according to the ESGEM guidelines (van Belkum et al., 2007). PCR
products were then stored at 20 C.3. Results
3.1. Study population and bacterial isolates
During the surveillance period 218 CRE strains from 146 differ-
ent patients were isolated, both from clinical samples and from
surveillance screening. 183 of the 218 isolates were identiﬁed as
KP, 19 were Escherichia coli (EC), 10 Enterobacter cloacae, 2 Klebsi-
ella oxytoca, 2 Enterobacter aerogenes, 1 Citrobacter freundii and 1
Providencia stuartii. 122 strains were isolated from rectal swabs,
65 from urinary samples, 14 from blood cultures, 8 from wounds,
7 from respiratory samples and 2 from indwelling catheters.
164 out of the 218 isolates were further analyzed with molecu-
lar techniques according to the eligibility criteria; they are summa-
rized in Table 2.
The temporal distribution per month (i.e. the time of the ﬁrst
isolation) of the KPC+ and VIM+ isolates is shown in the Fig. 1. At
least three small outbreaks can be identiﬁed: in August 2011,Table 2
Study synopsis. Legend: KPC = strains harboring the blaKPC gene; VIM = strains harboring t
the blaOXA-48 gene; IMP = strains harboring the blaIMP gene; AmpC + PL = strains with expre
loss or efﬂux pumps; ESBL + PL = strains expressing the extended-spectrum beta-lactamas
Microorganisms Resistance determinants
KPC VIM NDM OX
Klebsiella pneumoniae 73 44 3 2
Escherichia coli 4 3 4 1
Enterobacter cloacae 0 2 0 0
Klebsiella oxytoca 0 2 0 0
Enterobacter aerogenes 0 0 0 0
Citrobacter freundii 0 0 0 0
Providencia stuartii 0 0 1 0
Total 77 51 8 3
Fig. 1. Temporal distribution of the KPC+ ansustained mainly by VIM+ KP, in February 2012, sustained mainly
by KPC+ KP, as well as it happened in February 2014.
Among the 146 patients, 121 were colonized/infected by CPE
and 25 by strains with reduced susceptibility to carbapenems
due to other mechanisms.
Seventeen different episodes of infections were documented:
14 bacteraemias (among them, in 4 cases the strains were also iso-
lated from urinary samples, in 1 case from BAL and in 1 case from
vascular prosthetic material), 2 wound infections (WI) and 1 lower
respiratory tract infection (LRTI). The 14 episodes of bacteraemias
were sustained in 7 cases by VIM+ KP, in 4 cases by KPC+ KP, in 3
cases by E. cloacae with AmpC hyper-expression; the two WI by a
NDM+ KP and a KPC+ KP, whereas the LRTI by a KPC+ KP. We there-
fore documented 14 infections due to carbapenemase producers
strains in 121 patients (11.6%). All these patients have been previ-
ously colonized by the strain which caused the infection.
3.2. Phenotypic characterization and susceptibility to carbapenems
The disk diffusion synergy tests detected 77 possible KPC
strains (synergy only with the association meropenem – boronic
acid). 55 cases showed synergy only with the association merope-
nem-dipicolinic acid (deﬁning MBL-producers strains). Temocillin
showed an inhibition zone of more than 12 mm in 74 out of the
77 potential KPC isolates and only in one MBL positive isolate.
Among the 29 strains that did not show any synergistic effect with
the disk diffusion test, 7 were resistant to temocillin: 3 of those
strains proved to be blaOXA-48 positive, while 4 were not ampliﬁed
by the multiplex PCR used. The ESBL phenotype was detected in 14
cases, whereas in 11 cases a synergy for both ertapenem/boronic
acid and ertapenem/cloxacillin versus ertapenem alone conﬁrmed
the strain as being AmpC positive. These strains were usually onlyhe blaVIM gene; NDM = strains harboring the blaNDM gene; OXA-48 = strains harboring
ssion (or hyper-expression) of the AmpC determinant, possibly combined with porin
e resistance proﬁle, possibly combined with porin loss or efﬂux pumps.
Total
A-48 IMP AmpC + PL ESBL + PL
0 0 7 129
0 0 7 19
0 8 0 10
0 0 0 2
0 2 0 2
0 1 0 1
0 0 0 1
0 11 14 164
d VIM+ isolates analyzed in the study.
Table 3
MICs obtained for the different strains analyzed.
Imipenem MICs (Vitek2) Imipenem MICs (E-test strips)
P16 8 4 2 1 0.5 60.25 P32 16 8 4 2 1 0.5 60.25
KPC 58 13 2 3 1 0 0 58 8 4 3 4 0 0 0
VIM 28 13 10 0 0 0 0 22 5 9 9 5 1 0 0
NDM 7 0 0 0 0 0 0 5 0 1 1 0 0 0 0
OXA-48 3 0 0 0 0 0 0 0 0 1 1 0 1 0 0
OXA-48 + NDM 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0
AmpC + PL 1 0 0 1 2 3 4 0 0 0 2 1 3 3 2
ESBL + PL 0 0 1 1 3 5 4 0 1 0 1 1 6 2 3
Meropenem MICs (Vitek2) Meropenem MICs (E-test strips)
P16 8 4 2 1 0.5 60.25 P32 16 8 4 2 1 0.5 60.25
KPC 68 0 0 5 4 0 0 58 5 8 1 4 1 0 0
VIM 38 0 2 3 8 0 0 13 6 5 9 9 6 1 2
NDM 6 1 0 0 0 0 0 4 0 2 1 0 0 0 0
OXA-48 1 0 0 0 2 0 0 0 0 0 0 1 2 0 0
OXA-48 + NDM 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0
AmpC + PL 1 0 0 1 0 0 9 0 0 0 1 0 0 3 7
ESBL + PL 0 1 1 5 6 1 0 0 0 1 0 8 2 2 1
Ertapenem MICs (Vitek2) Ertapenem MICs (E-test strips)
= P8 4 2 1 60.5 = P32 16 8 4 2 1 0.5 60.25
KPC = 69 6 2 0 0 = 57 9 5 4 2 0 0 0
VIM = 23 21 2 0 5 = 18 4 6 12 7 3 0 1
NDM = 7 0 0 0 0 = 4 3 0 0 0 0 0 0
OXA-48 = 2 1 0 0 0 = 1 0 2 0 0 0 0 0
OXA-48 + NDM = 1 0 0 0 0 = 0 0 1 0 0 0 0 0
AmpC + PL = 2 3 4 1 1 = 1 0 0 1 6 3 0 0
ESBL + PL = 11 3 0 0 0 = 6 1 4 3 0 0 0 0
Table 4
Comparison of MICs obtained with different methods. IC = internal laboratory code; BM = broth microdilution technique.
Strain IC Isolate Resistance Meropenem MICs (mcg/ml)
Vitek-2 MIC test strip BM CLSI
4 Klebsiella pneumoniae VIM 1 4 4
10 Klebsiella pneumoniae KPC 1 8 4
14 Klebsiella pneumoniae KPC 2 16 4
22 Klebsiella pneumoniae KPC 2 8 8
23 Escherichia coli NDM 8 >32 8
30 Klebsiella pneumoniae KPC 2 16 8
35 Klebsiella pneumoniae KPC 2 32 4
49 Escherichia coli VIM P16 0.25 2
57 Klebsiella pneumoniae VIM P16 4 4
63 Klebsiella pneumoniae VIM P16 8 2
78 Klebsiella oxytoca VIM P16 4 0.5
83 Klebsiella oxytoca VIM P16 2 0.5
95 Klebsiella pneumoniae VIM P16 1 4
96 Klebsiella pneumoniae VIM P16 2 4
104 Klebsiella pneumoniae NDM P16 8 32
111 Klebsiella pneumoniae VIM P16 2 4
117 Enterobacter cloacae VIM P16 4 4
120 Klebsiella pneumoniae VIM P16 8 4
123 Klebsiella pneumoniae KPC P16 8 4
129 Klebsiella pneumoniae VIM P16 4 4
134 Klebsiella pneumoniae VIM P16 8 8
137 Klebsiella pneumoniae KPC P16 8 8
139 Klebsiella pneumoniae KPC P16 8 8
140 Klebsiella pneumoniae KPC P16 8 8
141 Klebsiella pneumoniae KPC P16 8 4
143 Klebsiella pneumoniae VIM P16 2 8
158 Klebsiella pneumoniae NDM P16 4 8
159 Klebsiella pneumoniae VIM 1 0.25 8
163 Klebsiella pneumoniae VIM P16 1 4
174 Klebsiella pneumoniae VIM P16 4 4
184 Klebsiella pneumoniae neg 8 2 8
187 Klebsiella pneumoniae KPC P16 2 2
188 Klebsiella pneumoniae VIM P16 8 32
190 Enterobacter cloacae VIM P16 2 4
193 Klebsiella pneumoniae KPC P16 4 4
197 Klebsiella pneumoniae KPC P16 8 4
212 Klebsiella pneumoniae VIM P16 2 2
218 Escherichia coli OXA-48 + NDM P16 1 4
219 Enterobacter aerogenes neg P16 4 8
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Fig. 3. RAPD proﬁles of KPC positive Klebsiella pneumoniae using primers NP5. Lanes
1 and 13, M = molecular markers, 100–3000 bp; lanes 2–11, the different proﬁles
obtained (number = strains’ label); lane 12, negative control. The proﬁles #24 and
#129 belong to two internal controls (i.e., strains previously supposed to be
unrelated with those analyzed).
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to both imipenem and meropenem) and for them hyperexpression
of the AmpC gene was supposed, eventually combined with a porin
loss.
The MICs of the analyzed strains are shown in Table 3. As
expected, all the blaKPC isolates showed MICs for carbapenems
higher compared with those obtained for strains harboring MBL
genes.
39 out of the 164 strains showed a difference of more than 2
logs between Vitek2 and gradient MIC for meropenem and/or the
other carbapenems. To evaluate the meropenem susceptibility for
these strains, they were further characterized using the broth mic-
rodilution technique, which appeared to have a better agreement
with the data provided by the gradient MIC technique (Table 4).
3.3. Molecular analysis of the carbapenemase genes
An example of the products of ampliﬁcation obtained is shown
in Fig. 2. The molecular analysis detected 77 strains harboring the
blaKPC gene (73 KP, 4 EC), 51 strains harboring the blaVIM gene (44
KP, 3 EC, 2 E. cloacae and 2 K. oxytoca), 8 strains with the blaNDM
gene (3 KP, 4 EC and one P. stuartii), 3 strains with the blaOXA-48
gene (2 KP, 1 EC). Interestingly, the 8 strains expressing blaNDM
were only isolated from 4 different patients: two had a contempo-
rary isolation of KP + EC, one had a single KP strain and in one
patient we isolated KP + EC + P. stuartii (one EC harboring both
blaNDM and blaOXA-48).
25 out of the 164 isolates (8 E. cloacae, 7 KP, 7 EC, 2 E. aerogenes
and 1 C. freundii) had a negative multiplex-PCR ampliﬁcation for all
the ﬁve targets tested.
3.4. Molecular typing
In a preliminary phase, 10 different clinical KP strains and an
internal control (i.e. a reference strain from UK NEQAS, which we
reasonably assumed to be unrelated to the strains we analyzed)
were studied using both ERIC-PCR and RAPD-PCR with ﬁve differ-
ent primers. The latter technique was able to provide a better dis-
crimination compared with the ERIC-PCR; for this reason, we used
this method to analyze the KP strains.
Considering the 73 KP-KPC+ strains, among the ﬁve different
primers used NP5 appeared to be the most discriminant. ThisFig. 2. The multiplex PCR performed in the study. Legend: M1 = molecular markers,
100–3000 bp; Ca = KPC+ control; Cb = NDM+ control; Cc = OXA-48+ control;
Cd = VIM+ control; Ce = IMP+ control. Other lines: #70, #183, #209 KPC+ isolates;
#106, #158 NDM+ isolates; #194 OXA-48+ isolate; #67 e #129 VIM+ isolates;
M2 = molecular markers, 100–600 bp.primer allowed the generation of 8 different ﬁngerprints (Fig. 3).
The largest cluster of strains accounted for 54 isolates, and four
proﬁles were characteristic for a single strain. Strains belonging
to the main cluster were isolated during all the study period. The
different ﬁngerprints were quite similar, with few polymorphic
bands.
The most discriminant primers for the 44 KP-VIM+ strains were
NP3 and NP5, which allowed to cluster the isolates in 6 different
group (with a total agreement in clustering for the two primers).
The largest group of KP-VIM+ isolates comprised 26 strains, with
a temporal distribution from July 2011 to June 2013.4. Conclusions
The study assessed the epidemiology of CRE over a 3-year
period in a relatively small geographical Italian province. Italy
is well known as a country where KP-KPC have spread widely
and nowadays is experiencing a situation of endemicity.
Recently, a paper of Gaiarsa et al. evaluated, from the genetic
point of view, the epidemiology of K. pneumoniae in Italy; some
of the KP strains harboring the blaKPC gene examined in that
paper were also analyzed in the present study and were clus-
tered with other strains isolated from different Italian settings
(Gaiarsa et al., 2014).
On the other hand, carbapenemase genes different from blaKPC
have so far been considered less of a problem, whose magnitude
has perhaps not been fully assessed, with only sporadic reports
being published (Gaibani et al., 2013; Kocsis et al., 2013). As an
example, although VIM carbapenemase was ﬁrstly recognized in
Italy (Lauretti et al., 1999), the exact magnitude of its distribution
in our country is still difﬁcult to establish.
The circulation of different carbapenemase genes was hereby
well documented: in our study population 4 different genes were
found (blaKPC was detected in 46.9% of the isolates, blaVIM in
31.9%, blaNDM in 4.3%, blaOXA-48 in 1.8%). No IMP genes were
detected in our study population. In 25 out of the 164 isolates
(15.2%) the decreased susceptibility to carbapenems (mostly to
ertapenem) was due to resistance mechanisms different from carb-
apenemase production.
The presence of carbapenemase was prevalent in KP, as
expected; and in this microorganism, the blaKPC gene was predom-
inant. However other genera and species of Enterobacteriaceae
were represented, harboring different resistance genes (Table 2).
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ing) was remarkable, since no discrepancies with the molecular
tests were found. In particular, the synergy with boronic acid
was so convincing that in our opinion the test appears to be strong
enough to deﬁne the strain as blaKPC producer without having to
resort to molecular testing.
By contrast, synergy testing with dipicolinic acid, although very
effective in our experience, cannot be considered valid enough for
surveillance purposes, as it is not able to discriminate among blaVIM
and blaNDM strains. In an endemic setting it is therefore necessary
to implement molecular analysis, perhaps in a second level center,
at least on a weekly basis.
Temocillin proved to be a useful surrogate marker of blaOXA-48,
but should always be used taking into account all other synergis-
tic effects. In particular, resistance to temocillin could be
considered a marker for blaOXA-48 only for strains with no other
evident synergies and the test should always be conﬁrmed
further (by growth on selective media and by molecular biology
as gold standard).
The molecular approach is also necessary to demonstrate the
contemporary presence of more than one resistance genes. A
patient included in the study had multiple injuries after a car crash
and in a three-month period we isolated in sequence a KP with a
blaOXA-48, an EC harboring both blaOXA-48 and blaNDM, a P. stuartii
with blaNDM and ﬁnally another EC with only blaNDM. He was a
native of North Africa with a recent transfer to Italy and this would
explain the presence of these carbapenemase, which are unusual in
our country.
In our setting, resistance to carbapenems is mediated by pro-
duction of carbapenemases as primary mechanism; however,
decreased susceptibility (mostly to ertapenem) can be detected
and is probably due to overexpression of AmpC, or sometimes to
a combination of AmpC and ESBL trait along with outer membrane
porin loss or hyper-expression of efﬂux pumps. Further phenotypic
assays are required to better deﬁne this situation. Molecular anal-
ysis should be always performed on these isolates: in the present
study two Enterobacter cloacae, well known to exhibit AmpC resis-
tance, also harbored the blaVIM gene.
14 out of the 121 patients with CPE developed infections,
which always happened in patients known to be colonized, as
showed by routine screening with rectal swabs. This low percent-
age of infection, compared with other data of the literature, is
most likely due to active surveillance, which detects a wide num-
ber of colonized patients and not only infected patients which are
the tip of the iceberg. Molecular typing using the RAPD technique
on the strains isolated from surveillance and from diagnostic cul-
tures in infected patients showed always the same ﬁngerprint,
indirectly demonstrating that infections always followed a previ-
ous colonization. Interestingly, half of the bacteraemias were sus-
tained by VIM+ KP.
A number of papers have recently stressed the clinical impor-
tance of carbapenems in treating infections due to CPE (Petrosillo
et al., 2013; Tzouvelekis et al., 2012). MIC values are important pre-
dictors of carbapenem efﬁcacy; nevertheless, it is well known that
automated instruments could fail in correctly evaluating the cor-
rect MICs of these microorganisms (Tenover et al., 2006;
Woodford et al., 2010). In this paper we demonstrated that in 39
out of the 164 strains analyzed (23.8%) there were major discrep-
ancies between the MICs obtained with automated instrument
and gradient MICs (i.e. more than two logs of difference), particu-
larly for MBL genes. The broth microdilution technique was in a
better agreement with the results obtained with the gradient
MIC, providing the same value in 13 cases (33.3%) or within one
log of difference in 11 cases (28.2%). This should be taken into con-
sideration while pondering over treatment options. Conﬁrmatory
techniques are therefore required before reporting carbapenemMICs values in CPE infections. It is interesting to note that all the
KP strains analyzed in the present study were susceptible to colis-
tin, and that the problem emphasized by Monaco et al. does not
seem to have an impact in our setting (at least for the moment)
(Monaco et al., 2014).
Regarding the molecular typing, we are aware of some limita-
tions in our study. MLST have not been performed on the strains
and RAPD are difﬁcult to be evaluated and compared. The deci-
sion to perform this kind of analysis was based on the fact that
the geographical setting was not particularly big and we postu-
lated the circulation of ST258 and ST512, as demonstrated in
our country (Giani et al., 2009, 2013); moreover, Deleo et al.
recently demonstrated that carbapenem-resistant ST258 KP is a
single genetic clone that has disseminated worldwide (Deleo
et al., 2014). The paper of Gaiarsa et al. also showed a very high
homogeneity of strains isolated in different Italian institutions
and ﬁve of the KP-KPC+ strains investigated in that paper have
been analyzed in the present study (Gaiarsa et al., 2014). Finally,
the main aim of the study was to assess the strains distribution
for local epidemiological purposes. In our experience, RAPD typ-
ing proved to be more discriminatory compared to the ERIC-
PCR technique. In order to minimize any potential problem
related to RAPD analysis and particularly to reduce the variables
due to the evaluation of different strains in different tests, we
performed the experiments every 2 weeks and in every new ses-
sion we included those strains which gave different proﬁles in
previous experiments (starting from the DNA stored from the ﬁrst
isolation). The variability in the ﬁngerprints we obtained was
indeed expected for strains carrying the blaVIM gene, whereas
more surprising considering the blaKPC strains. All the ﬁngerprints
we obtained were highly similar, although with some polymor-
phic bands that allowed to differentiate the strains. The major
group of KPC-KP consisted of 54 isolates and the clusters obtained
were congruent with the temporal distribution of the cases (i.e.,
in the two outbreaks we documented the presence of the same
RAPD-type).
Nonetheless, our molecular typing results clearly emphasize the
idea that, for surveillance protocols, every setting should perform
this kind of molecular analysis to trace the microorganisms, in
order to better understand if the control procedures in place are
adequate or ineffective.
Italy is a country where the problem of CPE has a major
impact – a situation which some Authors correctly describe as
the epidemiological ‘‘Italian scenario’’ (Nordmann, 2014). The
present study provides information about the magnitude of the
problem in a relatively small area, covering different aspects of
the problem from the microbiological point of view. The variabil-
ity in the resistance genes found, as well as the genetic variability
of the ﬁngerprint patterns obtained, and the problems in the cor-
rect evaluation of MICs values for carbapenems revealed a multi-
faceted reality, which should be known and correctly managed in
the different settings, especially in endemic situations or during
outbreaks.
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